All In Biotech

Drug Trial Radar · NCT04489888

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10).

Last checked: Nov 20, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

101

Actual

Start

Oct 27, 2020

Primary completion

Feb 20, 2023

Study completion Jun 28, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the efficacy and safety of pembrolizumab combined with carboplatin and paclitaxel as first-line treatment in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). No statistical hypothesis will be tested in this study.

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

  • PembrolizumabDrug

    Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle

  • CarboplatinDrug

    Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle

  • PaclitaxelDrug

    At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to ~25 months

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0265)

    New Haven, Connecticut

  • Helen F. Graham Cancer Center & Research Institute ( Site 0214)

    Newark, Delaware

  • Baptist MD Anderson Cancer Center ( Site 0215)

    Jacksonville, Florida

  • Orlando Health, Inc. ( Site 0216)

    Orlando, Florida

  • Regions Hospital ( Site 0227)

    Saint Paul, Minnesota

  • Washington University School of Medicine ( Site 0240)

    St Louis, Missouri

  • Erie County Medical Center-Head & Neck Surgery and Plastic & Reconstructive Surgery ( Site 0268)

    Buffalo, New York

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0262)

    Mineola, New York

  • Novant Health Presbyterian ( Site 0261)

    Charlotte, North Carolina

  • Novant Health Forsyth Medical Center ( Site 0266)

    Winston-Salem, North Carolina

  • UPMC Hillman Cancer Center ( Site 0253)

    Pittsburgh, Pennsylvania

  • Abington Hospital - Asplundh Cancer Center ( Site 0229)

    Willow Grove, Pennsylvania

  • Charleston Oncology ( Site 0231)

    Charleston, South Carolina

  • Virginia Commonwealth University ( Site 0233)

    Richmond, Virginia

  • IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0303)

    Buenos Aires, Argentina

  • Fundación Respirar ( Site 0306)

    Buenos Aires, Argentina

  • Instituto Medico Especializado Alexander Fleming ( Site 0301)

    Buenos Aires, Argentina

  • Hospital Provincial del Centenario ( Site 0304)

    Rosario, Santa Fe Province, Argentina

  • Centro Medico San Roque ( Site 0302)

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Orange Health Services ( Site 0106)

    Orange, New South Wales, Australia

  • The Townsville Hospital ( Site 0105)

    Douglas, Queensland, Australia

  • Gold Coast University Hospital ( Site 0103)

    Southport, Queensland, Australia

  • St Vincents Hospital Melbourne ( Site 0101)

    Fitzroy, Victoria, Australia

  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0402)

    São Paulo, Brazil

  • Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0401)

    São Paulo, Brazil

  • A.C. Camargo Cancer Center ( Site 0405)

    São Paulo, Brazil

  • Centro Regional Integrado de Oncologia ( Site 0403)

    Fortaleza, Ceará, Brazil

  • CETUS Hospital Dia Oncologia ( Site 0400)

    Belo Horizonte, Minas Gerais, Brazil

  • Liga Norte Riograndense Contra o Cancer ( Site 0404)

    Natal, Rio Grande do Norte, Brazil

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0406)

    Ijuí, Rio Grande do Sul, Brazil

  • Tom Baker Cancer Center ( Site 0014)

    Calgary, Alberta, Canada

  • Dr. H. Bliss Murphy Cancer Centre ( Site 0001)

    St. John's, Newfoundland and Labrador, Canada

  • Cancer Centre of Southeastern Ontario at Kingston General Hospital ( Site 0004)

    Kingston, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 0005)

    Toronto, Ontario, Canada

  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0003)

    Sherbrooke, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.